HLA-C and neoplasm: Consistent with the ideology that suppressed MHC expression on tumor cells is associated with poor anti-tumor immunity, several studies have identified markers of antigen presentation as correlates of response to immunotherapies targeting the PD-1/L1 axis6–8.